Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01500629 · ClinicalTrials.gov registry record · Early Phase 1
Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever
A Early Phase 1 study, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
NCT01500629: Completed Early Phase 1 study, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
NCT01500629 is a Early Phase 1 study that has completed, run by McNeil Consumer Healthcare Division of McNEIL-PPC. The registered enrollment target is 21 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01500629, a Early Phase 1 study, has completed, sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a new nasal spray can reduce the signs and symptoms of allergic rhinitis (hayfever). Subjects' participation in the study will last approximately 4 to 6 weeks, and each of three study visits during that time will last a few hours. Subjects will be required to have several tests done including allergy and breathing tests. They will be exposed to the item they are allergic to and will have small paper discs put in their noses. Subjects will also have the inside of their noses examined and will be asked questions about the level of their allergy symptoms.
Primary Outcome
The change from baseline in TNSS of sneezing, itchy nose, runny nose, and nasal congestion at 15 minutes after the first allergen challenge. TNSS was the sum of the severity of sneezing and the average score (left and right nostrils) for each of the following: itchy nose, runny nose, and nasal congestion. Severity of sneezing, itchy nose, runny nose, and nasal congestion were evaluated using a 4-point categorical scale where 0 = no symptoms, 1 = mild, 2 = moderate, 3 = severe. For the change fro
Interventions
- DEVICE C-1266-7
- DEVICE C-1266-6 (placebo)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2012-01 |
| Est. Completion | 2012-12 |
| Phase | Early Phase 1 |
What the finished NCT01500629 record still lists
NCT01500629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which C-1266-7 is the first listed.
NCT01500629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01500629 about?
NCT01500629 is a clinical study titled "Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever". The purpose of this study is to see if a new nasal spray can reduce the signs and symptoms of allergic rhinitis (hayfever). Subjects' participation in the study will last approximately 4 to 6 weeks, and each of three study visits during that time will last a few hours. Subjects will be required to h...
What is the current status of trial NCT01500629?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2012-01. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01500629?
The interventions under investigation include: C-1266-7 (DEVICE), C-1266-6 (placebo) (DEVICE).
Who is sponsoring clinical trial NCT01500629?
This trial is sponsored by McNeil Consumer Healthcare Division of McNEIL-PPC, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01500629's enrollment target sits among peer trials
21 1130th of 2000 higher than 844 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia